Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life

Nele Sigurs,1 Fatma Aljassim,2,3 Bengt Kjellman,4 Paul D Robinson,5,6 Fridrik Sigurbergsson,7 Ragnar Bjarnason,8 Per M Gustafsson2,4,9

ABSTRACT

Background An increased prevalence of asthma/recurrent wheeze (RW), clinical allergy and allergic sensitisation up to age 13 years has previously been reported in subjects hospitalised with respiratory syncytial virus (RSV) bronchiolitis in their first year of life compared with matched controls. A study was undertaken to examine whether these features persist into early adulthood, to report longitudinal wheeze and allergy patterns, and to see how large and small airway function relates to RSV infection and asthma.

Methods Follow-up at age 18 years was performed in 46 of 47 subjects with RSV and 92 of 93 controls. Assessments included questionnaire, clinical examination, skin prick tests, serum IgE antibodies to inhaled allergens, blood eosinophils, fraction of exhaled nitric oxide (FeNO), spirometry, multiple breath washout (lung clearance index, LCI) and dry air hyperventilation challenge.

Results Increased prevalence of asthma/RW (39% vs 9%), clinical allergy (43% vs 17%) and sensitisation to perennial allergens (41% vs 14%) were present at age 18 in the RSV cohort compared with controls. Persistent/relapsing wheeze associated with early allergic sensitisation predominated in the RSV cohort compared with controls (30% vs 1%). Spirometric function was reduced in subjects with RSV with or without current asthma, but not in asthmatic controls. LCI was linked only to current asthma, airway hyperresponsiveness and FeNO.

Conclusions Severe early RSV bronchiolitis is associated with an increased prevalence of allergic asthma persisting into early adulthood. Small airway dysfunction (LCI) is related to current asthma and airway inflammation but not to RSV bronchiolitis. Reduced spirometry after RSV may reflect airway remodelling (not requiring hospitalisation) during the first 3 years of life. Impaired lung function at age 10 has also been reported following hospitalisation in the first year with proven LTRI.5 Recently, data from a cohort previously hospitalised in the first 2 years of life and followed up at 18–20 years suggested that this impairment may persist into early adulthood.6 Histopathology studies of fatal RSV bronchiolitis demonstrate extensive damage to the airway epithelium and marked small airway obstruction,7 yet the presence of persistent small airway damage in later life is unclear. In adult asthma, small airway dysfunction is closely associated with bronchial hyper-responsiveness,8 9 a fundamental component of asthma correlated to disease severity.10

Our cohort represents infants aged <1 year with severe primary RSV bronchiolitis (43/47 6 months of age at hospitalisation). We have previously demonstrated increased prevalence of asthma or recurrent wheeze (RW) and allergic sensitisation compared with a matched control cohort at ages 3, 7 and 13 years.11–13 In this paper we present the 18-year follow-up data together with a longitudinal analysis of wheeze and allergy patterns. The primary aim was to see if the higher prevalence of asthma or RW, clinical allergy and allergic sensitisation persist at age 18. The secondary aims were to describe the wheeze patterns in both cohorts and to investigate how large and small airway function relate to severe RSV bronchiolitis, current asthma, airway hyper-responsiveness (AH) and markers of allergic inflammation.

METHODS

The study design is summarised in table 1. Forty-seven children aged <1 year hospitalised with RSV LRTI14 between December 1989 and April 1990 constituted the index group. An age- and gender-matched control group (n=95) was recruited from children attending the same child healthcare centres as the index cases. Both cohorts were followed up prospectively at ages 1, 3, 7, 13 and 18 years. Diagnosis of bronchiolitis was originally based on criteria published by Court,15 but was also consistent with other later published criteria.16 Demographic details at age 18 are given in table 2.

Structured questionnaires were completed at all follow-up time points to record demographic, hereditary and clinical symptoms of allergy or wheeze. A clinical examination was also performed. The investigations performed at each assessment are summarised in table 1. Details on skin prick tests (SPT) and serum IgE tests are given in our
Inhaled long-acting deviation scores (z-scores) using recently published normative (ImmunoCAP) was consistent throughout the study period.

Blood eosinophil counts

IgE to inhaled allergens (Phadiatop)

IgE to food allergens (Fx5)

Blood samples

Spirometry

Multiple breath washout (LCI)

FeNO

DACh

HDM, house dust mite; DACh, dry air hyperventilation challenge; LCI, lung clearance index; FeNO, fractional exhaled nitric oxide; RSV, respiratory syncytial virus.

Numbers in parentheses (RSV, controls) if differed from numbers followed up at that time point.

A skin prick test weal with a mean diameter $\geq 3$ mm was regarded positive. Phadiatop (Pharmacia Upjohn Diagnostics AB, Uppsala, Sweden) is a screening test for antibodies to inhaled allergens. Fx5 (Pharmacia Upjohn Diagnostics AB, Uppsala, Sweden) is a screening test for food allergens.

Spirometry was performed at baseline from age 7 and post-bronchodilator at ages 13 and 18 years, according to American Thoracic Society recommendations, and expressed as standard deviation scores (z-scores) using recently published normative data. Inhaled long-acting $\beta_2$ agonists were withheld for 24 h and short-acting $\beta_2$ agonists or Cromoglycates for 6 h prior to testing. Inhaled corticosteroids (ICS), if used, were not discontinued. Isocapnic dry air hyperventilation challenge (DACh) was performed after baseline spirometry at age 15 and 18 years (described in more detail in the online supplement). At age 18, prior to these lung function tests, the fraction of nitric oxide in expired air (FeNO) was measured in duplicate at an expiratory flow of 50 ml/s using the Niox Mino (Aerocrine, Stockholm, Sweden) and the mean FeNO result reported.

Multiple-breath washout (MBW) was performed before spirometry using sulfur hexafluoride (SF$_6$) as the marker gas and a mass spectrometer for gas analysis and as previously described in detail elsewhere. Lung clearance index (LCI) was calculated as the number of lung volume turnovers (ie, the cumulative expired volume divided by the functional residual capacity) needed to lower the end-tidal tracer gas concentration to 1/40th of the starting concentration. A high value of LCI thus indicates abnormal ventilation distribution. The mean LCI result from three MBWs in each subject was reported. In a previous study including healthy subjects, the mean, SD and upper limit of normal for LCI were reported as $1.5$ for age 1, $2$ for age 3, $2.5$ for age 7 and $3$ for age 13.

### Table 1

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Total number (RSV, controls)</th>
<th>% of cohort (RSV and controls)</th>
<th>Questionnaire</th>
<th>Examination</th>
<th>Skin prick tests (RSV, controls)</th>
<th>Egg white</th>
<th>Cat</th>
<th>Dog</th>
<th>Horse</th>
<th>Birch</th>
<th>Timothy</th>
<th>Mugworth</th>
<th>HDM (D. pteronyssinus)</th>
<th>HDM (D. farinae)</th>
<th>mould (Cladosporium herbarum)</th>
<th>mould (Alternaria alternata)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>47, 93</td>
<td>100</td>
<td>×</td>
<td>×</td>
<td>(47, 92)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
<tr>
<td>1.5, 2 and 2.5</td>
<td>47, 93</td>
<td>100</td>
<td>×</td>
<td>×</td>
<td>(45, 89)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>(45, 89)</td>
<td>×</td>
<td>×</td>
<td>(42, 87)</td>
<td>(46, 89)</td>
<td>×</td>
<td>×</td>
<td>(42, 87)</td>
</tr>
<tr>
<td>3</td>
<td>47, 93</td>
<td>100</td>
<td>×</td>
<td>×</td>
<td>(44, 89)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>(42, 87)</td>
<td>×</td>
<td>×</td>
<td>(41, 85)</td>
<td>(44, 86)</td>
<td>×</td>
<td>×</td>
<td>(41, 85)</td>
</tr>
<tr>
<td>7</td>
<td>47, 93</td>
<td>100</td>
<td>×</td>
<td>×</td>
<td>(44, 86)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>(42, 88)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
<td>(46, 89)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
</tr>
<tr>
<td>13</td>
<td>46, 92</td>
<td>96.5</td>
<td>×</td>
<td>×</td>
<td>(41, 85)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>(42, 88)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
<td>(41, 85)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
</tr>
<tr>
<td>18</td>
<td>46, 92</td>
<td>96.5</td>
<td>×</td>
<td>×</td>
<td>(44, 86)</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>(42, 88)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
<td>(46, 89)</td>
<td>×</td>
<td>×</td>
<td>(41, 88)</td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Variable</th>
<th>RSV (n = 46)</th>
<th>Controls (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>65 (12)</td>
<td>70 (13)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174 (10)</td>
<td>174 (10)</td>
</tr>
<tr>
<td>Parental atopy</td>
<td>30/46 (65%)</td>
<td>52/92 (65%)</td>
</tr>
<tr>
<td>Parental asthma</td>
<td>18/46 (39%)</td>
<td>25/92 (27%)</td>
</tr>
<tr>
<td>Tobacco smoke exposure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>10/45 (22%)</td>
<td>14/92 (15%)</td>
</tr>
<tr>
<td>Passive (family member)</td>
<td>19/45 (42%)</td>
<td>40/92 (43%)</td>
</tr>
<tr>
<td>Indoor furred pets</td>
<td>24/46 (52%)</td>
<td>56/92 (61%)</td>
</tr>
</tbody>
</table>

Mean (SD) or proportions (percentages) of subjects are given. No significant differences were seen between the groups.

### Table 3

<table>
<thead>
<tr>
<th>Wheeze pattern</th>
<th>Age (years)</th>
<th>RSV (n = 46)</th>
<th>Controls (n = 92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never wheeze</td>
<td>3</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>Transient wheeze</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Remitting/intermittent</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Persistent/relapsing</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Male, female distribution shown in parentheses.

Statistical evaluation refers to comparison of proportion of subjects in the different wheeze pattern groups in the RSV and control cohorts: **p<0.001.

RSV, respiratory syncytial virus.
normality (ULN; mean + 1.96 SD) for LCI were 6.33, 0.43 and 7.17, respectively. At each follow-up time point, asthma was defined as ≥3 episodes of physician-verified wheeze and RW as ≥3 episodes of parent-reported wheeze. Definitions of the wheezing patterns over time are shown in table 3. Allergic rhinoconjunctivitis (ARC) or clinical allergy was defined as rhinitis/conjunctivitis occurring at least twice following exposure to a particular allergen and unrelated to infection. Atopic dermatitis (AD) was defined as a pruritic, chronic or chronically relapsing non-infectious dermatitis. Allergic sensitisation implied occurrence of IgE antibodies estimated by SPT and/or serum IgE tests. Current disorder denotes symptoms over the last 12 months. Active and passive smoke exposures, the presence of pets in the household, and atopic or allergic heredity were assessed by questionnaire. A positive history of atopic disease (AD, ARC or asthma) in first-degree relatives (parents or siblings) was based on physician diagnosis.

### Statistical analyses

Yates’ corrected χ² test was used for estimation of differences in prevalence among groups and subgroups. One-way ANOVA was used for parametric continuous variables and Tukey HSD for subsequent group comparisons, if the overall F-test was significant. A Mann–Whitney test was used to test group differences for non-parametric continuous variables. 95% CIs for mean and median differences were calculated. χ² tests for trend were used to assess the combined influence of group allocation (RSV vs control) and a parental history of physician-diagnosed asthma on asthma/RW, ARC and sensitisation at age 18. Pearson correlation tests were used to assess correlation of parametric data, while the Spearman rank test was used for non-parametric data. Kaplan–Meier survival analysis was used to compare time free from diagnosis of asthma, ARC, positive Phadiatop test or positive SPT to any perennial allergen at a follow-up station; p values based on Mantel-Cox log rank tests were calculated. Multivariate logistic regression analyses were performed to establish risk factors for asthma/RW, asthma alone and ARC at age 18. ORs with 95% CI and p values were reported. Additionally, conditional logistic regression tests were performed to adjust for any degree of residual confounding due to the constitution of the groups during the study period. SPSS Version 15.0 software for Windows (SPSS Inc, Chicago, Illinois, USA), SPSS SamplePower 2.0 software and CI Analysis software version 2.1.2 (Trevor Bryant, University of Southampton) were used for the statistical analyses.

### RESULTS

Forty-six of the 47 subjects with RSV and 92 of the 93 controls were followed up to 18 years of age. The demographic details of the two cohorts at age 18 are summarised in table 2, and from age 1–18 years in table E1 in the online supplement. No significant differences were seen at age 18.

#### Cross-sectional data at age 18

Current asthma/RW was documented in 18 of 46 (39%) subjects with RSV and 8 of 92 (9%) controls (p = 0.001). Current asthma alone was found in 15 of 46 (33%) subjects with RSV and 6 of 92 (7%) controls (p<0.001). ARC was diagnosed in 20 of 46 subjects with RSV (43%) and 16 of 92 (17%) controls (p = 0.002). No difference was found in the prevalence of AD (5 of 46 (11%) subjects with RSV vs 8 of 92 (9%) controls).

The prevalence of sensitisation determined by SPT was significantly increased in the RSV cohort compared with controls to any animal dander (cat, dog, horse) (53% vs 11%; p = 0.005) or any perennial (animal danders and house dust mites (HDM)) (41% vs 14%; p = 0.001) (see table E2 in online supplement). A higher prevalence of positive Phadiatop responses was seen in the RSV cohort (56% vs 28%, p = 0.005) (see table E2 in online supplement). For the whole cohort, the most commonly identified specific IgE antibodies performed in those testing positive to Phadiatop screening were to ‘any perennial’ (39 of 126, 31%), and were significantly increased in subjects with RSV compared with controls (51% vs 21%; p = 0.001).

Airway function data are summarised in table 4. Reduced spirometric airway function (forced expiratory volume in 1 s (FEV₁), ratio of FEV₁ to forced vital capacity (FVC) and forced expiratory flow at 25–75% FVC (FEF₂₅₋₇₅)) was documented in the RSV cohort compared with controls, but LCI did not differ. AHR, bronchodilator response and blood eosinophil cell counts were greater in the RSV cohort than in the controls, but FeNO

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Airway function and inflammatory markers in RSV and control groups at age 18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RSV (n = 46)</td>
</tr>
<tr>
<td><strong>Resting</strong></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (z-score)</td>
<td>−0.28 (0.93)</td>
</tr>
<tr>
<td>FEV₁/FVC (z-score)</td>
<td>−0.68 (0.85)</td>
</tr>
<tr>
<td>FEF₂₅₋₇₅ (z-score)</td>
<td>−0.60 (0.77)</td>
</tr>
<tr>
<td>LCI</td>
<td>6.63 (0.52)</td>
</tr>
<tr>
<td><strong>Challenge (DACH)</strong></td>
<td></td>
</tr>
<tr>
<td>Fall in FEV₁ (%)</td>
<td>4.7 (0.0–37.8)</td>
</tr>
<tr>
<td><strong>Post-bronchodilatation</strong></td>
<td></td>
</tr>
<tr>
<td>Rise in FEV₁ (%)</td>
<td>5.9 (0.0–10.5)</td>
</tr>
<tr>
<td>FEV₁ (z-score)</td>
<td>0.16 (0.71)</td>
</tr>
<tr>
<td>FEV₁/FVC (z-score)</td>
<td>−0.04 (0.88)</td>
</tr>
<tr>
<td>FEF₂₅₋₇₅ (z-score)</td>
<td>−0.01 (0.78)</td>
</tr>
<tr>
<td><strong>Inflammatory markers</strong></td>
<td></td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>14 (6–84)</td>
</tr>
<tr>
<td>Blood eosinophil counts (×10⁹/l)</td>
<td>0.20 (0.04–0.57)</td>
</tr>
</tbody>
</table>

Data are shown as mean (SD) or median (range). For normally distributed data, differences between the two groups are shown with 95% CI for the mean values and for non-normally distributed data as the 95% CI for the medians. *p < 0.05, **p < 0.01, ***p < 0.001.

For exact number of subjects in RSV and control group performing each test, see Table 1. DACH, isocapnic dry air hyperventilation challenge; FEF₂₅₋₇₅, forced expiratory fraction at 25–75% forced vital capacity; FeNO, fraction exhaled nitric oxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; LCI, lung clearance index; ppb, parts per billion; RSV, respiratory syncytial virus.
Asthma

Table 5  Airway function and inflammatory markers in RSV versus control subjects with or without current asthma/RW at age 18 years

<table>
<thead>
<tr>
<th></th>
<th>Current asthma/RW</th>
<th>No current asthma/RW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RSV (n=18)</td>
<td>Controls (n=8)</td>
</tr>
<tr>
<td>Resting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (z-score)</td>
<td>-0.64 (0.85)</td>
<td>0.05 (0.77)</td>
</tr>
<tr>
<td>FEV1/FVC (z-score)</td>
<td>-0.89 (0.52)</td>
<td>0.08 (1.37)</td>
</tr>
<tr>
<td>FEF25–75 (z-score)</td>
<td>-0.89 (0.71)</td>
<td>-0.06 (0.86)</td>
</tr>
<tr>
<td>LCI</td>
<td>6.88 (0.63)</td>
<td>6.89 (0.25)</td>
</tr>
<tr>
<td>Challenge (DACh)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall in FEV1 (%)</td>
<td>8.5 (0.0–37.8)</td>
<td>7.5 (0.3–42.6)</td>
</tr>
<tr>
<td>Rise in FEV1 (%)</td>
<td>6.5 (0.0–10.2)</td>
<td>2.5 (0.0–9.9)</td>
</tr>
<tr>
<td>FEV1 (z-score)</td>
<td>-0.18 (0.79)</td>
<td>0.25 (1.05)</td>
</tr>
<tr>
<td>FEF25–75 (z-score)</td>
<td>-0.23 (0.63)</td>
<td>0.48 (1.08)</td>
</tr>
<tr>
<td>FEF25–75 (z-score)</td>
<td>-0.29 (0.76)</td>
<td>0.48 (0.72)</td>
</tr>
<tr>
<td>Inflammatory markers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>22 (6–84)</td>
<td>15 (7–51)</td>
</tr>
<tr>
<td>Blood eosinophils (x10³/l)</td>
<td>0.33 (0.06–0.57)</td>
<td>0.16 (0.04–0.31)</td>
</tr>
</tbody>
</table>

Data are shown as mean (SD) or median (range).

For normally distributed data differences between the two groups are shown with 95% CI for the mean values and for non-normally distributed data as the 95% CI for the medians.

*p<0.05, **p<0.01, ***p<0.001.

DACh, isocapnic dry air hyperventilation challenge; FEF25–75, forced expiratory fraction at 25–75% forced vital capacity; FeNO, fraction exhaled nitric oxide; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; LCI, lung clearance index; ppb, parts per billion; RSV, respiratory syncytial virus; RW, recurrent wheeze.

was not. FEV1/FVC and FEF25–75 remained lower in the RSV cohort after bronchodilatation. Subjects with RSV had lower spirometry results than the controls, irrespective of current asthma/RW diagnosis (table 5). Spirometry findings were similar in controls with or without current asthma/RW. LCI was significantly raised in subjects with RSV (p=0.006) and controls (p=0.053) with current asthma/RW compared with corresponding subjects without asthma (see table E3 in online supplement). Only LCI differed significantly between the controls with and those without current asthma/RW (see table E4 in online supplement). In the RSV cohort, the maximum percentage fall in FEV1 after dry air challenge correlated significantly with LCI (r² =0.44; p<0.001), FeNO levels (r² =0.26; p<0.001) and with blood eosinophil counts (r² =0.12; p=0.011).

![Figure 1](http://thorax.bmj.com/)

**Figure 1** Proportion (%) with (A) current asthma/recurrent wheeze, (B) current allergic rhinoconjunctivitis, (C) current positive Phadiatop test and (D) current positive skin prick test to perennial allergens in respiratory syncytial virus (RSV) and control cohorts with respect to heredity for asthma. χ² test for trend was used in all graphs and error bars denote 95% CI.
but not with spirometry results (see table E5 in online supplement). Among the subjects with current asthma/RW, regression analyses also demonstrated significant relationships between LCI and the maximum percentage fall in FEV₁ after dry air challenge ($r^2=0.26; p=0.005$) and between LCI and FeNO ($r^2=0.29; p=0.003$).

**Family history and other risk factors for asthma and ARC at age 18**

A family history of asthma and atopy did not differ between the RSV and control cohorts at age 18. A number of risk factors for current asthma/RW, current asthma and current ARC, respectively, were assessed using multivariate logistic regression analyses including both cohorts. For current asthma/RW and for current asthma, the risk factors included were: allocation (RSV/control), gender, domestic furred pets in the first year of life, parental smoking in the first year of life, own smoking at age 18, current ARC of the subjects themselves, physician-diagnosed parental ARC and physician-diagnosed parental asthma.

For current asthma/RW only RSV (OR 6.2; 95% CI 2.0 to 19.2; $p<0.001$) and current ARC of the subjects (OR 6.1; 95% CI 2.1 to 18.1; $p<0.001$) were significant independent risk factors. For current asthma alone, similar results were found (RSV: OR 7.2 (95% CI 2.1 to 23.9; $p<0.001$); current ARC: OR 4.4 (95% CI 1.4 to 14.0; $p<0.001$)).

The risk factors included in the analysis for current ARC were the same, except for current ARC of the subjects. Only RSV (OR 3.6; 95% CI 1.6 to 8.5; $p=0.005$) was a significant independent risk factor. Corresponding conditional logistic regression tests gave similar results (see table E6 in the online supplement).

Numerically, the RSV subgroup with a parental history of asthma had a higher prevalence of asthma/RW, ARC and positive sensitisation than the RSV subgroup without parental asthma, but no significant differences were found ($p=0.058$–0.308). The statistical power to detect significant differences between the RSV subgroups was <50%. For the two cohorts analysed together, however, the combination of RSV allocation and history of parental asthma resulted in significant trends for disease and sensitisation (figure 1A–D).

**Longitudinal data over the entire study period: subjects with RSV versus controls**

Kaplan–Meier survival plots for time free from asthma diagnosis, ARC diagnosis, positive Phadiatop test or positive SPT are shown in figure 2A–D. The RSV group had significantly shorter time free from these diagnoses and test findings.

Reduced lung function in the RSV cohort was evident from the age of 7 years (mean (SD) baseline FEF$_{25-75}$ z-scores in RSV $0\pm20\pm40\pm60\pm80\pm100$).
group vs controls at age 7: −0.65 (1.04) vs −0.22 (0.95) (95% CI 0.05 to 0.77; p=0.025); at age 13: −0.58 (0.77) vs −0.12 (0.78) (95% CI 0.17 to 0.74; p=0.002). At ages 13 and 18 a greater fall in FEV₁ after DAcH was seen in subjects with RSV.¹³

Wheeze patterns up to age 18 years
The persistent/relapsing asthma/RW pattern occurred more frequently in the RSV cohort with fewer non-wheezers in the RSV group (table 3). No difference in other wheeze patterns was seen. All 14 individuals with a persistent/relapsing asthma/RW pattern in the RSV cohort had current symptoms on at least two time points (seven on all four and six on three occasions). Asthma/RW was noted from age 5 in 11 of 14 subjects in this group. The one individual in the control group with persistent/relapsing asthma had symptoms at all occasions from age 7. Nine subjects with RSV (7 with persistent/relapsing asthma/RW and 2 with late onset asthma/RW) and 5 control subjects with late-onset asthma/RW were treated with ICS (p=0.002). The persistent/relapsing group (14 RSV and 1 control) was characterised by the highest prevalence of co-existing ARC (figure 5A) and sensitisation (figure 5B). The significantly higher prevalence of sensitisation was evident at ages 5, 7 and 13, and similarly for ARC at age 7 and 13 (data not shown).

At 18 years of age the persistent/relapsing wheeze group had significantly lower airway function (FEV₁, FEV₁/FVC and FEF₂⁵–₇₅ z-scores), higher LCI and AHR than the non-wheeze group (table 6). Bronchodilator response, FeNO and blood eosinophil counts were significantly increased compared with never wheezers only in the persistent/relapsing asthma/RW group.

DISCUSSION
The previously reported over-representation of asthma (and asthma/RW), clinical allergy and allergic sensitisation in this RSV cohort persisted into early adulthood. The high prevalence of current asthma/RW in the RSV cohort was due to a high proportion of subjects with early-onset allergy-associated wheezing persisting through childhood and adolescence, and was accompanied by reduced airway function, elevated FeNO and eosinophil counts. A history of hospitalisation for RSV bronchiolitis was the only significant risk factor identified at age 18 for current asthma/RW, asthma alone or ARC.

At age 18, spirometry results were reduced in subjects with RSV with or without current asthma/RW compared with corresponding controls, but subjects with RSV without current asthma did not show evidence of small airway dysfunction as measured by LCI. Spirometry results showed no relationship with AHR or markers of allergic inflammation. In contrast, small airway dysfunction (LCI) correlated with current asthma, AHR and FeNO, a marker of ongoing allergic airway inflammation.

This controlled follow-up study and its findings are unique. It describes the development of asthma and allergy prospectively after severe primary RSV bronchiolitis in the first year life, and has involved several follow-up time points from infancy to young adulthood, all with very high attendance rates. The subsequent high frequency of early-onset allergic asthma persisting to age 18 has not previously been reported. Only two other prospective studies of RSV have documented a high prevalence of early sensitisation comparable to ours at 1 year¹¹ and 3 years of age.²²

The debate between a causal or genetic predisposition relationship between RSV and asthma has continued for decades and cannot be answered by this study. Two recent large registry-based studies have attempted to answer this question, with each declaring opposite conclusions.²³ ²⁴ The weaknesses in the study designs and the difficulties in answering this question have been highlighted in a recent editorial.²⁵ RSV-positive infants with wheezing may include both those with primary RSV LRTI or those with an existing non-asthmatic or asthmatic wheezing disorder exacerbated by RSV. In our cohort, 91% of the index subjects were 6 months or younger when admitted and only one had a previous history of lower airway symptoms, which strongly suggests that our cohort comprises subjects with early primary severe RSV LRTI. It is thought that early infancy, with a relatively Th-2 skewed immune system, may constitute a particularly vulnerable period of life for subsequent development of asthma following severe viral LRTI.³ Viral airway infections and atopy may interact in a multiplicative way to promote asthma development in young childhood.³⁶ In addition, predisposition to both early severe RSV bronchiolitis and allergic sensitisation may be related to the interleukin (IL)-13/IL-4 gene locus.²⁷ Potential hereditary susceptibility to RSV bronchiolitis has also been reported.²⁸

Potential confounding factors do exist within our cohort. Mallia and Johnston²⁹ have previously suggested that the higher rate of asthma in our RSV cohort compared with controls could be due to selection bias generated by the selection of controls contemporaneously from the same child healthcare centres as the index cases. Theoretically, our selection process during an ongoing RSV epidemic could generate controls with a lower susceptibility for severe RSV bronchiolitis and a lower risk for subsequent allergic asthma if severe RSV bronchiolitis and subsequent allergic asthma are markers of the same genotype. There are two main reasons

Figure 3 Proportion (%) of subjects with (A) allergic rhinoconjunctivitis in different wheezing phenotypes (overall χ² p<0.001, ***p<0.01, **p<0.001 vs the no-wheeze phenotype) and (B) positive Phadiatop test in different wheezing phenotypes (overall χ² p<0.001, ***p<0.001 vs the no-wheeze phenotype). Error bars denote 95% CI. RSV, respiratory syncytial virus.
In summary, this study shows that severe primary RSV bronchiolitis in the first year of life is frequently followed by allergic asthma persisting into early adulthood. Subjects with RSV without current asthma/RW have reduced airway function as measured by spirometry. Ventilation inhomogeneity, a measure of small airway function, is normal in subjects with RSV without current asthma but is linked to current asthma, AHR and ongoing airway inflammation. Our findings suggest that early severe RSV bronchiolitis has lifelong consequences of allergic asthma and airway remodelling.

Acknowledgements The authors thank Mrs Gunilla Holmgren Wallmyr for skilful advice.

Funding The study was supported by grants from the Regional Health Care Authority of West Sweden, from Borås Hospital, the Fokus Foundation and SeBe’s Fund.

Competing interests None.

Ethics approval This study was conducted with the approval of the Human Research Committee of the Medical Faculty at the University of Gothenburg. All parents and subjects gave consent to the study.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Asthma


Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life

Nele Sigurs, Fatma Aljassim, Bengt Kjellman, Paul D Robinson, Fridrik Sigurbergsson, Ragnar Bjarnason and Per M Gustafsson

Thorax 2010 65: 1045-1052 originally published online June 27, 2010
doi: 10.1136/thx.2009.121582

Updated information and services can be found at:
http://thorax.bmj.com/content/65/12/1045

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2011/12/16/thx.2009.121582.DC1

References
This article cites 38 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/65/12/1045#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Asthma (1782)
- Bronchiolitis (112)
- Bronchitis (235)
- TB and other respiratory infections (1273)
- Inflammation (1020)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/